47
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Novel Methods in Vascular and Lymphatic Physiology

      Submit here by June 30, 2025

      About Journal of Vascular Research: 1.8 Impact Factor I 3.4 CiteScore I 0.486 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Studies on the Mechanism of the Venoconstrictor Activity of Ergotamine on Isolated Canine Saphenous Veins

      research-article
      ,
      Journal of Vascular Research
      S. Karger AG
      Veins, Ergotamine, α-Adrenoceptors

      Read this article at

      ScienceOpenPublisher
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ergotamine stimulates spiral strips from dog saphenous veins in concentrations about 2,000 times lower than that of noradrenaline, but its maximal effect is only 20% compared to that of noradrenaline. Phentolamine antagonizes the ergotamine effects. The pA<sub>2</sub> value for phentolamine against ergotamine is 6.94, and for phentolamine against noradrenaline it is 6.96. Cocaine potentiates noradrenaline effects but does not change ergotamine effects. The results suggest that the venoconstrictor activity of ergotamine is mediated mainly via stimulation of α-adrenoceptors.

          Related collections

          Author and article information

          Journal
          JVR
          J Vasc Res
          10.1159/issn.1018-1172
          Journal of Vascular Research
          S. Karger AG
          1018-1172
          1423-0135
          1974
          1974
          18 September 2008
          : 11
          : 3
          : 183-190
          Affiliations
          Biological and Medical Research Division, Sandoz Ltd., Basel
          Article
          158011 Blood Vessels 1974;11:183–190
          10.1159/000158011
          faf1e6ae-24e5-4e86-95e1-4219f4e71122
          © 1974 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 11 February 1974
          : 12 June 1974
          Page count
          Pages: 8
          Categories
          Research Paper

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Ergotamine,Veins,α-Adrenoceptors

          Comments

          Comment on this article

          Related Documents Log